Ginkgo Bioworks Holdings (DNA) Change in Cash (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Change in Cash came in at -$23.7 million in Q1 2026, up 90.53% YoY from -$12.4 million in Q1 2025, and down 142.77% on a QoQ basis from $55.4 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Change in Cash (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Change in Cash data on file, last reported at -$23.7 million in Q1 2026.
- Quarterly Change in Cash rose 90.53% year-over-year to -$23.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$166.7 million (up 68.65% YoY) and the FY2025 annual result came in at -$393.4 million, down 2.48% from the prior year.
- Change in Cash eased to -$23.7 million in Q1 2026, from $55.4 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $55.4 million in Q4 2025 to a low of -$250.3 million in Q1 2025.
- A 5-year average of -$82.6 million and a median of -$94.4 million in 2025 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2023 — Change in Cash slumped 536.35% — and 2025, when it surged 199.31%.
- Tracing DNA's Change in Cash over 5 years: stood at $24.1 million in 2022, then tumbled by 536.35% to -$105.0 million in 2023, then surged by 46.88% to -$55.8 million in 2024, then surged by 199.31% to $55.4 million in 2025, then tumbled by 142.77% to -$23.7 million in 2026.
- The last three Change in Cash figures came in at -$23.7 million (Q1 2026), $55.4 million (Q4 2025), and -$94.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -16.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.65 Mn |
| Mar 31, 2026 | -23.70 Mn |
| Dec 31, 2025 | 55.41 Mn |
| Sep 30, 2025 | -94.39 Mn |
| Jun 30, 2025 | -104.05 Mn |
| Mar 31, 2025 | -250.34 Mn |
| Dec 31, 2024 | -55.80 Mn |
| Sep 30, 2024 | -114.20 Mn |
| Jun 30, 2024 | -111.47 Mn |
| Mar 31, 2024 | -102.37 Mn |
| Dec 31, 2023 | -105.04 Mn |
| Sep 30, 2023 | -77.44 Mn |
| Jun 30, 2023 | -86.61 Mn |
| Mar 31, 2023 | -110.91 Mn |
| Dec 31, 2022 | 24.07 Mn |
| Sep 30, 2022 | -75.33 Mn |
| Jun 30, 2022 | -115.01 Mn |
| Mar 31, 2022 | -57.08 Mn |
| Dec 31, 2021 | -172.37 Mn |
| Sep 30, 2021 | 1.51 Bn |